SynthesisBiomedica : revista del Instituto Nacional de Salud2025
A meta-analysis about the relationship of serum nesfatin-1 levels in patients with type 2 diabetes mellitus
Synthesis in Biomedica : revista del Instituto Nacional de Salud, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nesfatin-1, a peptide coded by the NUCB2 gene, has recently been implicated in the regulation of insulin synthesis and glucose homeostasis. These findings suggest a potential role for nesfatin-1 in the etiology of type 2 diabetes mellitus. Objective: To analyze the relationship between circulating levels of nesfatin-1 and type 2 diabetes mellitus. Material and methods: We used PubMed, Scopus, and DOAJ platforms to search published articles from 2012 to 2024. The keywords used were “diabetes mellitus”, “diabetes”, “type 2 diabetes”, “nesfatin-1”, “NUCB2”, “ELISA”, “plasma”, and “serum”. We included all case-control and cross-sectional studies conducted in humans, with full-text availability, and written in English or Spanish. Results: We included eight studies comprising 305 patients with type 2 diabetes mellitus and 205 controls. The results showed a significant relationship between nesfatina-1 and type 2 diabetes mellitus with a high heterogeneity index (t2 = 3.91; χ2 = 349.63, p < 0.00001; I2 = 98%). Conclusions: The results show a significant relationship between nesfatin-1 and type 2 diabetes mellitus, supporting its potential use as a biomarker for this disease
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.